Abbvie Inc - Global License Agreement to Focus on Development of FG-M701, a Tl1a Antibody, for Treatment of Inflammatory Bowel Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.